MicroQuin has developed first-in-class context-dependent therapies for a novel and broadly impactful target for cancer. Unlike the new drugs coming to market in immuno-oncology, precision therapy, and cell therapy, which take hyper-focused approaches to patient treatment, our therapy offers is a universal method for targeted cell death.


MicroQuin uniquely treats cancer as a disease state, rather than target specific attributions for a particular person or cell type that could be limited to a small subset, may mutate, or may develop immunity, amongst other challenges.

Reach out to learn more about our science and development

© 2019 MicroQuin